It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in ...

New approach recruits the body’s immune system to attack glioblastoma while reducing treatment-related toxicity.

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy ...

Cancer immunotherapy company Liminatus Pharma has agreed to pay out shares worth $320 million to buy CAR-T biotech InnocsAI. | Cancer immunotherapy company Liminatus Pharma has agreed to pay out ...

Targeting KMA seeks to spare normal immunoglobulin-producing plasma cells, differentiating from BCMA-directed CAR T ...

Researchers have tested a gene-edited stem cell transplant designed to shield healthy blood-forming cells from powerful ...

Engineered CAR‑T cells suppressed HIV off medication in two people — promising but early. Larger trials are needed.

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...

A team led by LMU physician Sebastian Kobold has found a way to allow the body's immune system to destroy solid tumors. In 2024, Professor Sebastian Kobold's research group at LMU University Hospital ...

Targeted extended circulation LNP achieved complete B cell depletion in nonhuman primates through highly specific in vivo CD8+ T cell engineering ...

We also report on a new use for artificial intelligence that could help eliminate some racial inequities in heart disease diagnoses.

CAR T-cell therapy has been hugely successful in treating certain types of tumours, and stiffening up cancer cells beforehand ...